(6th and 7th Left): Principal Investigator TICO Nigerian Study Center, Dr Nnakelu Eriobu and TICO Study Co-Investigator, Dr Vivian Kwaghe with TICO research study team at the Infectious Disease Center in University of Abuja Teaching Hospital (UATH), Abuja.
IHVN Senior Technical Advisor Pediatric and Adolescent HIV Dr. Nadia Sam Agudu training health care providers in Abuja, Nigeria
Findings from a multi-country study published in the Lancet Journal have revealed that concentrated solution of antibodies donated by patients who have recovered from COVID-19 is ineffective in treating hospitalized COVID-19 patients.
A recently published study involving researchers from the Institute of Human Virology Nigeria (IHVN), and Ahmadu Bello University, Zaria, Nigeria, has revealed that African children and adolescents hospitalized with COVID-19 experience high mortality rates.
IHVN Senior Technical Advisor, Dr Emilia Iwu (second left) meets with the Ensuring Quality Access and Learning for Mothers and Newborns in Conflict-Affected Contexts (EQUAL) team at the IHVN Campus in Abuja.
The Institute of Human Virology Nigeria (IHVN) has announced a new partnership that aims to improve maternal and newborn health in conflict-affected countries through the creation of a multi-country research consortium. With funding provided by UK Aid from the UK government, the $11.3 million contract will be led by the International Rescue Committee (IRC) alongside IHVN, Johns Hopkins Bloomberg School of Public Health, and its university-wide Center for Humanitarian Health, the Somali Research and Development Institute, and Université Catholique de Bukavu (Democratic Republic of Congo).